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Abstract To elucidate a genetic predisposition to major
depressive disorder, we investigated two polymorphisms
(−31T/C and −511C/T) in the interleukin-1beta promoter
region in patients who suffered from major recurrent
depression. The aim of the current work was to compare
alleles and genotype layout between patients with major
recurrent depression and healthy people. We would like to
indicate such combination of genotypes which corresponds
with major recurrent depression. Correlations between
genotypes for analyzed polymorphisms and number of
episodes, number of points in Hamilton Depression Rating
Scale, and age of onset were investigated as well. The study
group consisted of 94 patients diagnosed with major
recurrent depression. The control group included 206
healthy individuals. Both groups involved representatives
of Caucasian population. Genotyping of polymorphisms
was performed by using PCR-RFLP technique. A specific
haplotype, composed of the C allele at −31 and the T allele
at −511, has a tendency to have a statistically significant
difference (p=0.064) between patients and control group.
Correspondence analysis revealed that genotype T/T at −31
and genotype C/C at −511 are associated with major
recurrent depression. No association was found between
genotypes for studied polymorphic sites and number of
episodes, number of points in Hamilton Depression Rating
Scale, and age of onset.
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Introduction
In developed countries, major depressive disorder (MDD)
is one of the most important psychiatric problems of both
genders (Ustun et al. 2004; Andrews et al. 2005). Inpatients
with MDD, increase in peripheral inflammatory biomarkers
including inflammatory cytokines, which have access to brain
and affect brain function, was observed. These observations
pointed a possible correlation of MDD with the activation of
t h ei n f l a m m a t o r yr e s p o n s e( S l u z e w s k a1999;K u b e r ae ta l .
2000; Khairova et al. 2009;M i l l e re ta l .2009). Systemic
administration of interleukin-1beta (IL-1beta) to rats leads to
arising of depression-like symptoms including anhedonia,
anorexia, and disturbed sleep pattern (Connor and Leonard
1998). The same symptoms are also typical for cytokine
immunotherapy treatment (Capuron et al. 2000).
Several studies have found that the IL-1beta level
increases in the cerebrospinal and blood (Anisman et al.
1999; Owen et al. 2001). Furthermore, elevated cerebro-
spinal fluid levels correspond with the duration of illness
and age of onset (Dantzer 2004). However, in the data that
have been published so far, no significant increase was
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et al. 2000; Kagaya et al. 2001).
Taking into account the close correlation between IL-
1beta and MDD, two polymorphisms in IL-1beta gene in
patients with major recurrent depression (MRD) have been
investigated in this study. Both polymorphisms are in the
promoter region of the IL-1beta gene, at position −31T/C
(rs1143627) and −511C/T (rs 16944), respectively. The aim
of the current work was to compare alleles and genotype
layout between patients group and controls. The polymor-
phism −511C/T was selected for analysis because in vitro
level of IL-1beta secretion correlates with genotype in −511
position (Pociot et al. 1992). To our knowledge, the
polymorphism −31T/C and haplotype analysis of two IL-
1beta polymorphisms have been investigated in MRD for
the first time. We would like to select such combination of
genotypes for both polymorphic sites, which corresponds
with MRD. We would also like to investigate linkage
disequilibrium between the two analyzed polymorphisms as
well correlations between these polymorphisms and number
of episodes, number of points in Hamilton Depression
Rating Scale (HDRS; Hamilton 1967), and age of onset.
Materials and Methods
Subjects
The patient group consisted of 94 individuals [67 (71.3%)
women and 27 (28.7%) men, mean age 53.8±9.4 (median=
54.0; 24–81)] meeting the Diagnostic and Statistical Manual
ofMentalDisorders,FourthEdition,Text Revision(DSM-IV-
TR) criteria for major recurrent depression. The diagnosis has
been assigned based on the Structured Clinical Interview for
DSM-IVAxis I Disorders-Clinician Version (First et al. 1997)
by two independent experienced psychiatrists. Additionally,
bipolar spectrum was excluded according to Ghaemi et al.
(2001) criteria as well as by the application of the Mood
Disorder Questionnaire (Hirschfeld et al. 2000).
The control group consisted of 206 healthy individuals
[75 (36.4%) females and 131 (63.6%) males age- and
gender-matched somatically healthy blood donors (age
range, 20–65 years, mean age 42.3±8.8 (median=43.0;
20–61)]. Before sampling, it was verified by direct
interview if they had current psychiatric problems or family
history of psychiatric or neurological disorders. Both
patients and controls were biologically unrelated individu-
als of Caucasian Polish origin living in Silesia region.
Genotyping
Genomic DNA was isolated from the blood samples, and
the quality of extracts was checked electrophoretically.
For −31T/C polymorphic site, a 420-bp PCR fragment
was amplified using the primers as described in Kimura et
al. (2004) .P C Rc o n d i t i o n sw e r ea sf o l l o w s :9 6 ° Cf o r1m i n ,
followed by 35 cycles of 94°C for 50 s, 50°C for 1 min, 72°C
for 40 s, and final elongation at 72°C for 10 min. The PCR
products were digested with AluI. The allele T has three cut
sites resulting in four fragments of the following sizes: 247,
97, 57, and 20 bp. The C allele has two cut sites, resulting in
fragments of sizes 344, 57, and 20 bp. In each stage of the
experiment, two control samples with C/C and T/T genotypes
were used.
For −511C/T polymorphic site, a 304-bp PCR fragment
was amplified, and products were digested as described in
Katila et al. (1999).
Statistical Analysis
The distribution of variables was evaluated by the Shapiro–
Wilk test. Homogeneity of variance was assessed by the
Levene test. The significance of the differences in alleles as
well as genotype frequencies in control and patient groups
were compared either by the χ
2 test or with the maximum
likelihood χ
2 test. The odds ratio was used. One-way
multivariate analysis ANOVA or Kruskal–Wallis ANOVA,
according to distributions, was used. Associations of
Case n=94 (%) Controls n=206 (%) χ
2 p
−31T/C Genotypes C/C 8 (8.5) 29 (14) 3.11 0.2111
T/C 58 (61.7) 131 (63.7)
T/T 28 (29.8) 46 (22.3)
Alleles T 114 (60.7) 223 (54) 2.22 0.1362
C 74 (39.3) 189 (46)
−511C/T Genotypes C/C 42 (44.7) 76 (36.9) 1.84 0.3985
C/T 49 (52) 120 (58.3)
T/T 3 (3.3) 10 (4.8)
Alleles T 55 (293) 140 (34) 1.31 0.2524
C 133 (70.7) 272 (66)
Table 1 Genotypes and allele
frequencies in the patient and
control groups
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polymorphisms in the IL-1beta gene between control group
and patients with MRD were assessed with the correspon-
dence analysis with hierarchical clustering (Ward’s method
and Euclidean distance). Statistical calculations were
performed by using the Statistica 8.0 software (www.statsoft.
com), R software (cran.r-project.org/), and SNPStats
(bioinfo.inconcologia.net).All p values were two-tailed, and
significance level was set at p<0.05.
Results and Discussion
Previous studies indicated that −31T/C polymorphic site
is a part of TATA box, and T allele enhanced binding of
transcription factors. In consequence, the presence of T
allele is associated with increase in the production of
IL-1beta (El-Omar et al. 2000;C h e ne ta l .2006). On the
other hand, some reports not only did not show any
significant association between −31T/C polymorphisms
and IL-1beta protein production in vitro (Santtila et al.
1998) but also pointed at allele C to be connected with
higher IL-1beta expression in vivo (Hwang et al. 2002).
Several studies indicated that −511C/T polymorphic site is
implicated in differential expression of IL-1beta protein as
well (Hall et al. 2004). Other authors did not record the
positive correlation between allelic differences and tran-
scriptional activity of IL-1beta gene, but observed the
influence of −511 polymorphic site on transcriptional
activity in the context of −31 polymorphic site more
through interactions than direct contact with trans-activat-
i n gp r o t e i n s ,w h i c hb i n dt or e g u l a t o r ye l e m e n t sw i t h i nt h i s
region (Chen et al. 2006).
Quite strong linkage disequilibrium between analyzed
polymorphic sites (LD analysis, D′=0.6294; r=0.4994;
p<0.0001) was observed. Previous published reports showed
that polymorphism −511C/T is in almost complete linkage
disequilibrium with the functional polymorphism −31T/C
(El-Omar et al. 2000, 2001;H a l le ta l .2004;M i s e n e r
et al. 2008).
We have not found an association in alleles and genotype
layout for both polymorphisms between control and patient
group (Table 1). Our results support some previous studies
which postulated the lack of association between −511C/T
polymorphism with MRD and bipolar disorder, respectively
(Yu et al. 2003; Papiol et al. 2004). Similarly, studies
concentrated on −31T/C polymorphisms revealed absence
of association with MRD (Misener et al. 2008). On the
other hand, an association of the −511C/T polymorphism
with Alzheimer’s disease (Grimaldi et al. 2000; McCulley
et al. 2004) and depressive symptoms in schizophrenia has
been found (Rosa et al. 2004). It should be emphasized here
that current results may be different with reference to some
other similar experiments because our patient group is
homogeneous and includes individuals only with major
recurrent depression.
Haplotype analysis has been also provided, but haplo-
type predispose to MRD was not identified (Table 2).
However, a tendency to have a statistically significant
difference was observed in patients carrying T allele at
position −511 and C allele at position −31 in IL-1beta gene
promoter. In a single SNP analysis, allele C at −31
polymorphic site reduced promoter activity in relation to
allele T, but substantially increased its activity in the
context of allele T at −511 polymorphic site (Chen et al.
2006). Some authors suggest that this specific haplotype is
associated with increase in IL-1beta protein secretion (Hall
et al. 2004). In the present experiment, significant differ-
ences may appear when analysis has been conducted on a
larger group of patients.
−31T/C −511C/T Frequency Depression Control Odds ratio (95% CI) p
T C 0.4940 0.5428 0.4712 1.00
C T 0.2573 0.2290 0.2697 1.66 (0.97–2.85) 0.0640
C C 0.1810 0.1646 0.1890 1.45 (0.85–2.45) 0.1700
T T 0.0677 0.0636 0.0701 1.41 (0.60–3.31) 0.4300
Table 2 Haplotype frequencies
in the patient and control groups
Fig. 1 Results of correspondence analysis. Dashed regions show
clusters yielded with hierarchical agglomeration with the Ward’s
method and the Euclidean distance. D major recurrent depression,
C control
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of genotype T/T for −31 polymorphic site and genotype
C/C at −511 position is connected with MRD, while
heterozygous combination at both polymorphic sites is
connected with controls (Fig. 1). These results are in
agreement with previous reports which described the
same differences in relation to allele distribution. Co-
presence of allele T at −31 polymorphic site and allele C
at −511 polymorphic site influenced the binding of
transcription factors to the IL-1beta gene promoter region
(El-Omar et al. 2000;C h e ne ta l .2006).
We did not found an association between genotypes of
both studied polymorphic sites and number of episodes,
number of points in HDRS, and age of onset. Previously,
Levine et al. (1999) demonstrated that IL-1beta level was
positively correlated with the severity of depression. Simi-
larly, Yu et al. (2003) suggest that polymorphism −511C/T
may be related to the severity of MDD and early insomnia in
MDD patients.
There are several factors that may limit the power to
detect strong association by some statistical analysis for
polymorphisms investigated in this work. Our group of
patients is rather small, but it is worth to remark that the
group is homogeneous, and only patients diagnosed with
MRD were included in the experiment. It is conceivable
that some statistical significance might be detected in an
experiment of a large study group, especially in the case of
some parameter analyses, a tendency to have a statistical
significance has been observed.
In conclusion, this study was carried out to investigate
two polymorphisms in IL-1beta gene. Obtained data
provide evidence suggesting that genotypes T/T at −31
polymorphic site and C/C in −511 polymorphic site
correspond with MRD. We also investigated that poly-
morphisms are in quite strong linkage disequilibrium.
Current results support the role of polymorphisms in IL-
1beta gene as a genetic risk factor for MRD.
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